Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614246 · ClinicalTrials.gov registry record · Phase 2
Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb
A Phase 2 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 215
- Enrollment target
NCT04614246 is a Phase 2 study that was terminated before completion, run by Bayer. The registered enrollment target is 215 participants.
The verdict
NCT04614246, a Phase 2 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 215 participants
- Enrollment target
Study Summary
The purpose of this study is to assess safety and efficacy of BAY 1817080 compared to elagolix and placebo in women with symptomatic endometriosis. Study details include: * Study duration: 155 up to 285 days * Treatment duration: 84 days * Visit frequency: 3 laboratory every 2 weeks for participants on BAY 1817080 or placebo
Interventions
- DRUG Placebo
- DRUG Elagolix
- DRUG BAY1817080
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2021-01-29 |
| Est. Completion | 2022-05-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04614246
The ClinicalTrials.gov registry entry for NCT04614246 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04614246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04614246 about?
NCT04614246 is a clinical study titled "Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb". The purpose of this study is to assess safety and efficacy of BAY 1817080 compared to elagolix and placebo in women with symptomatic endometriosis. Study details include: * Study duration: 155 up to 285 days * Treatment duration: 84 days * Visit frequency: 3 laboratory every 2 weeks for participant...
What is the current status of trial NCT04614246?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 215 participants. The study started on 2021-01-29. Estimated completion is 2022-05-03.
What interventions are being tested in trial NCT04614246?
The interventions under investigation include: Placebo (DRUG), Elagolix (DRUG), BAY1817080 (DRUG).
Who is sponsoring clinical trial NCT04614246?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.